Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab and Balstilimab in Resectable Colorectal Cancer
NCT05571293Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of botensilimab and balstilimab in colorectal cancer (CRC) (3 cohorts), sponsored by Weill Cornell Medicine. Primary endpoints: Pathological Overall Response Rate, Number of Participants Who Experience Potentially Treatment-related SAEs and 2 more. Started Mar 2023; status: completed.
02
Drugs
botensilimabbalstilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05571293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05571293.